130 results about "Mucoprotein" patented technology

The application belongs to the field of intestinal microbiology, and discloses a new mucinophilic Akkermansia with improved obesity and glycolipid metabolism, wherein the mucinophilic Akkermansia strain is Akk-101 and AMY001. The preservation number of Akk-101 is CGMCC No. 40786, and the preservation number of AMY001 is CGMCC No. 46141. The Akk-101 and AMY001 strains in the application are different from standard strains in nucleotide consistency and physiological and biochemical indexes, have better acid-base tolerance and colonization capacity than the standard strains, can more effectively inhibit the accumulation of liver cell lipids, reduce the fat deposition in nematodes, and have the effects of weight loss and improvement of glycolipid metabolism, so that related products can be effectively developed based on the strains.

The invention relates to the technical field of microorganisms, in particular to a culture medium and a method for culturing Ackermania muciniphila for activating Amuc-1260 by using lambda-carrageenan as a carbon source, according to the culture method, the lambda-carrageenan is used for replacing a traditional carbon source, thallus growth and proliferation can be remarkably promoted, the effect is optimal under the condition of 2.00 g / L, and the culture cost is low. Compared with the conventional carbon source (glucose), the carbon source is improved by 92.91%. Further research finds that the lambda-carrageenan can induce the Akk bacteria to up-regulate the expression of glycoside hydrolase such as Amuc-1260 and enhance the activity of pathways such as glycosaminoglycan degradation, amino acid metabolism and insulin signals, so that the metabolic adaptability and energy utilization efficiency of the bacteria are improved. Meanwhile, the Akk bacteria secrete more functional short-chain fatty acids such as acetic acid, propionic acid and the like under the condition, and have the effects of regulating intestinal health and maintaining metabolic homeostasis. The invention provides a new theoretical basis and technical support for large-scale culture of Akk bacteria and development of a metabiotic product.

Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.

The invention relates to the technical field of microorganisms, and discloses Ackermann muciniphila, a combined microbial agent thereof and application of the Ackermann muciniphila in inflammatory enteritis. The invention provides Akkermansia muciniphila AIML-559, and the preservation number of the Akkermansia muciniphila AIML-559 is CGMCC (China General Microbiological Culture Collection Center) No. 34246. The invention relates to a combined microbial agent, which is characterized by comprising Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34300). The combined microbial agent is prepared from the following raw materials: Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 The ackermann mucophil combined microbial inoculum is suitable for treatment intervention of inflammatory bowel disease (IBD), and can relieve weight loss, hemolysis, anemia, diarrhea, intestinal bleeding and other symptoms of IBD mice.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

The invention discloses a Su semi-poria cocos-tangerine decoction for relieving high secretion of mucus in an acute exacerbation stage of chronic obstructive pulmonary disease as well as a preparation method and application of the Su semi-poria cocos-tangerine decoction, and relates to the technical field of traditional Chinese medicine compositions. The Su semi-poria cocos and orange soup is prepared from 8-10 g of fructus perillae, 8-10 g of rhizoma pinellinae praeparata, 8-10 g of ginger processed cortex magnoliae officinalis, 8-10 g of radix peucedani, 4-6 g of fried semen brassicae, 8-10 g of fried semen raphani, 8-10 g of fried rhizoma atractylodis macrocephalae, 12-15 g of poria cocos, 4-6 g of fried pericarpium citri reticulatae and 2-3 g of cortex cinnamomi. Clinical application of the Su semi-poria cocos and tangerine decoction prepared by the invention shows that compared with a control group which is only treated by conventional western medicine, the secretion amount of mucoprotein MUC5AC is greatly reduced, traditional Chinese medicine symptom integral, CAT score and mMRC score are greatly reduced, symptoms of a patient are obviously relieved, and no adverse reaction occurs. Therefore, the Su semi-poria cocos and orange soup can relieve high secretion of mucus with the syndrome of AECOPD turbid phlegm obstructing lung and improve clinical symptoms of patients, and is good in safety.

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.

The application discloses a hybridoma cell strain 6F92E10, a monoclonal antibody thereof and application thereof, and belongs to the technical field of biotechnology.The application provides a hybridoma cell strain secreting an anti-mucinophilic Akkermansia monoclonal antibody.The antibody secreted by the hybridoma cell strain only combines with AKKermansia and does not cross-react with other common intestinal bacteria.In addition, the application solves how to detect the adhesion and colonization of mucinophilic Akkermansia in the colon of a mouse by using the prepared monoclonal antibody through an indirect immunofluorescence localization experiment, and expands the application range of the antibody.

The invention discloses a bionic cross-linked film-forming repair dressing containing mussel mucoprotein and a preparation method of the bionic cross-linked film-forming repair dressing, and relates to the technical field of medical instruments. The bionic crosslinking film-forming repair dressing containing the mussel mucoprotein is prepared from the following components in parts by weight: 30 to 40 parts of bionic crosslinking agent, 25 to 35 parts of humectant, 10 to 20 parts of natural high polymer material, 1 to 10 parts of mussel mucoprotein, 1000 parts of purified water and 5 to 15 parts of pH regulator. PEG-DOPA is formed through cross-linking, the DOPA content and stability are remarkably improved, the adhesion-repair-anti-inflammatory effect of mussels mainly depends on the dopa content, the effect of the dressing is remarkably enhanced through improvement of the DOPA content and stability, the dressing is more convenient to use through the flexibility change of a film, the dressing is more suitable for dynamic and wet wounds, and the application range of the dressing is widened. The medicine has a remarkable effect on chronic ulcer and burn.

The invention belongs to the technical field of biological medicine, and discloses ovomucoprotein glycopeptide and application thereof. According to the application of the ovomucoprotein glycopeptide in preparing the medicine for preventing or treating the alcohol-induced acute gastric mucosal lesion, the percentage of the gastric mucosal lesion area can be reduced to 1.0% or below when the ovomucoprotein glycopeptide is used for protection. The invention creatively discovers and verifies that the glycopeptide derived from ovomucin has a remarkable protective effect on acute gastric mucosal lesion induced by alcohol. According to the discovery of the application, the application field of the natural active ingredient ovomucin is definitely expanded to the protection of acute gastric mucosal lesion for the first time, the technical problem that efficient and natural gastric mucosal protection ingredients are lacked in the prior art is solved, and a brand-new material basis and a clear direction are provided for developing a novel gastric mucosal protective agent.

The invention belongs to the field of microorganisms and medicine health care, and relates to an ackermania muciniphila strain and application thereof, the preservation number of the ackermania muciniphila strain is CGMCC (China General Microbiological Culture Collection Center) No.34370, and a 16SrDNA (Deoxyribose Nucleic Acid) sequence of the ackermania muciniphila strain has 93% similarity with a sequence shown as SEQ ID NO: 1. The new ackermania muciniphila strain (AKKBC300) is separated from a healthy human body and has good safety; good tolerance to low pH value and bile salt is shown in vitro, and it is indicated that the compound can reach the intestinal tract through the upper digestive tract and play a role; according to the present invention, genomics analysis results prove that the bacterial strain contains the gene Akkermansia BC00573 with high homology with the known probiotic functional protein Amuc1100, such that the molecular basis is provided;

The invention relates to application of serum mucoid or Tax1 binding protein 1 in preparation of a medicine for treating medicine-induced liver injury or organ ischemia-reperfusion injury. Experiments prove that by using an adeno-associated virus (AAV) carrying an Orm2 gene, ORM2 recombinant protein or knocking down a TAX1BP1 gene, liver injury and liver failure, ischemia reperfusion injury of the liver, ischemia reperfusion injury of the kidney and ischemia reperfusion induction of intestines induced by APAP treatment can be effectively relieved, and the application has the advantages that the liver injury and liver failure, the ischemia reperfusion injury of the kidney and the ischemia reperfusion induction of the intestine can be effectively relieved; and a new target spot and a new treatment method are provided for treating the ferroptosis-related organ injury.

The present application relates to the field of microorganisms, in particular to a mucinophilic Akkermansia strain and application thereof, the mucinophilic Akkermansia has a preservation number of CCTCC NO: M 20241304.The mucinophilic Akkermansia AKK-86 of the present application has good effects of promoting iron absorption, improving iron metabolism, and relieving intestinal inflammation.In addition, the mucinophilic Akkermansia of the present application can also promote the production of GLP-1, and has potential application in reducing blood sugar and weight loss products.

The invention provides a preparation method of anti-inflammatory soothing and repairing microspheres based on Trichoderma reesei-Lactobacillus johnsonii two-stage fermentation. According to the preparation method, Trichoderma reesei fermentation products, Lactobacillus johnsonii metabolites, specific plant active ingredients and mussel mucoprotein are included. According to the invention, the mussel mucoprotein-trichoderma reesei-lactobacillus johnsonii ternary synergistic anti-inflammatory antibacterial system microspheres are innovatively constructed, the targeted delivery efficiency of active ingredients is remarkably improved through the adhesion characteristic of mussel mucoprotein, and the technical bottlenecks of poor permeability and short action time of a traditional anti-inflammatory preparation are solved. A multi-strain synergistic fermentation process is adopted, beta-glucan secreted by trichoderma reesei and short-chain fatty acid generated by lactobacillus johnsonii generate a synergistic anti-inflammatory effect, and meanwhile, an enzymolysis technology is combined to realize efficient conversion of plant active ingredients, so that the inhibition effect on key inflammatory factors such as TNF-alpha and IL-6 is remarkably enhanced. According to the system, inflammatory pathways such as NF-kappa B and the like are regulated and controlled through multiple targets, the inflammatory reaction is reduced while the growth of pathogenic bacteria is inhibited, a remarkable broad-spectrum antibacterial and anti-inflammatory synergistic effect is shown, and an innovative solution is provided for developing an efficient and safe anti-inflammatory antibacterial preparation.

The invention relates to the technical field of biological medicines, in particular to application of extracellular vesicles of Ackermann muciniphila in preparation of trichina control products. Experiments prove that by supplementing the AKK bacterium extracellular vesicles, the intestinal flora of a mouse can be remarkably improved, the immune balance of a host is regulated, and the pathological change of the intestinal tract of the mouse can be improved. Experimental results show that the AKK bacterium extracellular vesicles have a certain protection effect on trichina infected mice and have the advantages of being efficient, safe, easy to produce on a large scale and the like, and a brand new technical solution is provided for prevention and treatment of trichinosis.

The invention discloses a preparation method of Chinese yam mucin anti-drag hydrogel. The preparation method comprises the following steps: crushing Chinese yam blocks and deionized water to obtain a Chinese yam mucus mixture; centrifuging, standing and layering, extracting supernate, and filtering to obtain a plant extracting solution; purifying by adopting a reverse osmosis method, and air-drying to obtain Chinese yam mucoprotein; the preparation method comprises the following steps: adding gelatin into a PBS solution, heating and stirring, then adding N, N-dimethylformamide and methacrylic anhydride, heating and stirring, dialyzing, and freeze-drying to obtain a gelatin derivative grafted with carbon-carbon double bonds; the preparation method comprises the following steps: adding a gelatin derivative into deionized water, heating and stirring, adding Chinese yam mucoprotein, N, N '-methylene bisacrylamide and ammonium persulfate, stirring, centrifugally defoaming, and drying to obtain the Chinese yam mucoprotein drag-reducing hydrogel. According to the preparation method of the Chinese yam mucoprotein anti-drag hydrogel, Chinese yam mucoprotein macromolecular chains are connected into a network structure by using N, N '-methylene bisacrylamide molecules, so that water-soluble Chinese yam mucoprotein is prevented from being dissolved and lost in a water body, and long-term lubrication and anti-drag are realized.

The invention relates to an application of inactivated ackermania muciniphila Akk09 in preparation of a postbiotic preparation for controlling body weight and improving obesity. The preservation number of the ackermania muciniphila Akk09 is CCTCC (China Center For Type Culture Collection) NO: M 20242401. According to the present invention, the new use of the Ackermania muciniphila Akk09 is developed, the research basis is provided for the wide application of the Ackermania muciniphila Akk09, the brand new strategy for controlling body weight and improving obesity is developed, the inactivated Ackermania muciniphila Akk09 strain has significant effects on controlling body weight and improving obesity, and the inactivated Ackermania muciniphila Akk09 strain has significant application prospects. The Ackermania muciniphila Akk09 strain is a probiotic, the safety of the product is high, and the resistance is not easy to generate.

The invention discloses a tumor inhibition preparation based on Ackermania muciniphila, and belongs to the field of tumor medicine.AKK and tumor cells are mixed according to a certain proportion and jointly injected into a mouse body, and it is found that AKK can inhibit growth of the tumor cells and can survive for at least 7 days in the tumor cells; in addition, the effect of AKK in a living body is better than that of AKK in a dead body, the AKK is mixed in a bioactive solution to prepare the tumor inhibition preparation based on Ackermania muciniphila, and an auxiliary agent glucosamino acid conjugate can be added in the preparation of the tumor inhibition preparation, so that the AKK-based tumor inhibition preparation can be used for preparing the tumor inhibition preparation based on Ackermania muciniphila and the AKK-based tumor inhibition preparation based on Ackermania muciniphila. The glucosamine acid conjugate has a glucosamine group and a 2-aminothiazole-5-carboxylic acid ester group, which are coupled by a succinic acid. The ackermansiella muciniphila-based tumor inhibition preparation provided by the invention has a good inhibition effect on tumor cells, is good in safety and can be used for preparing anti-tumor drugs.

The application belongs to the technical field of microorganisms, and provides application of Propionibacterium freudenreichii subsp. shermanii in preparation of products for improving constipation and depression, wherein the Propionibacterium freudenreichii subsp. shermanii NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number is CCTCC NO: M 20241429. The inventors find that NHNK-616 has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, and up-regulating expression of intestinal defensin and mucin genes, and therefore can be used for preparing products for improving constipation and depression.

The present invention relates to a linker unit-cytotoxic small molecule drug, an antibody specifically binding to target mucoprotein 17 (MUC17), an antibody drug conjugate and uses thereof, and a composition and a detection system containing the antibody molecule, the linker unit-cytotoxic small molecule drug and the antibody drug conjugate.

This invention discloses a clean modification process for yam starch with high slow-digestible starch content, belonging to the field of clean starch modification technology. It aims to solve the problems of existing modification processes relying on exogenous additives, high costs, and difficulty in balancing starch digestibility and stability. This invention uses fresh yam as raw material and obtains a co-precipitation system retaining endogenous mucoprotein through isoelectric point sedimentation. Based on this, vacuum alternating pulsed steam treatment is used, utilizing pressure difference and thermal effects to promote the migration of endogenous proteins at the starch particle interface and construct a stable composite structure. Subsequently, annealing is performed under high humidity conditions to induce ordered rearrangement of molecular chains. This process, without adding exogenous substances, precisely controls the starch structure, significantly increases the slow-digestible starch content, and improves the processing stability of the product. It has advantages such as being green and clean, highly safe, and highly functional.

The invention relates to medicinal and edible meal replacement powder for regulating intestines and stomach and a preparation method thereof. The fried coix seed powder and the Chinese yam powder are used as main grain base materials and have the effects of strengthening the spleen, nourishing the stomach and repairing intestinal mucosa, the banana powder and the apple pectin rich fibers are matched and can moisten the intestines and regulate the intestines and the stomach, the poria cocos powder can strengthen the spleen, soothe the nerves and inhibit harmful bacteria, and the endothelium corneum gigeriae galli powder and the fried maltol have the effects of promoting digestion, relieving stasis, promoting the circulation of qi and relieving flatulence. The sweet osmanthus powder and coconut powder are supplemented, so that the fragrance and taste of the meal replacement powder can be improved, essence components are not needed, and the components are more natural and harmless. In the preparation process, coix seeds and malt are stir-fried to stimulate fragrance, low-temperature drying of Chinese yam retains mucus protein, after irradiation sterilization treatment, effective components are effectively retained, component loss is avoided, and the gastrointestinal regulation effect of the meal replacement powder is achieved through combination of traditional processing and a modern food technology.

The invention relates to the technical field of microcapsule preparation, in particular to a preparation method of a probiotic microcapsule. The preparation method comprises the following steps: mixing a probiotic suspension and a tris (2-carboxyethyl) phosphine solution, and carrying out a reduction reaction to obtain a thiolated probiotic suspension; and mixing the thiolated polysaccharide and the thiolated probiotic suspension, and carrying out a covalent ligation reaction to obtain the probiotic microcapsule. According to the preparation method disclosed by the invention, disulfide bonds on the surfaces of the probiotics are reduced into free mercaptan through simple chemical reaction, so that thiolated polysaccharide and the probiotics are covalently bound, and the polysaccharide and the probiotics are more firmly bound. The microcapsule prepared from the modified polysaccharide and the probiotics can also be combined with mucoprotein rich in the mucous layer of the intestinal tract to generate a catalyst-free thiol-disulfide exchange reaction, and colonization is carried out at the mucous layer in the intestinal tract, so that better intestinal disease treatment and probiotic benefits are generated.

The present invention provides an isolated Akkermansia muciniphila, a composition containing same, and a use thereof, which can be used for treating, preventing, or alleviating obesity, metabolic disorders caused by obesity, diabetes, inflammation, liver and kidney disease, liver disease, cardiovascular and cerebrovascular diseases, tumors, etc.

The invention discloses mucoprotein nano-selenium gas motor hydrogel as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method of the mucoprotein nano-selenium gas motor hydrogel comprises the following steps: adding a carbonyl compound and selenite into an emulsifier solution, and adding a reducing agent for mixing reaction to obtain a nano-selenium gas motor, oxidized mucoprotein and the nano-selenium gas motor are mixed, then a cross-linking agent is added, the oxidized mucoprotein is subjected to a cross-linking reaction to form gel, and the mucoprotein nano-selenium gas motor hydrogel is obtained. The mucoprotein nano-selenium gas motor hydrogel is constructed by wrapping a gas motor into a mucoprotein hydrogel delivery system, the mucoprotein nano-selenium gas motor hydrogel can be specifically delivered to a colitis disease part through rectal administration, and meanwhile, the safe and controllable release and mucous membrane protection effects of the nano-selenium gas motor are realized; therefore, a new thought is provided for treating enteritis.

This invention discloses a method for studying the mechanism by which the mucoprotein channel 1 (TRPML1) regulates the outflow of zinc ions from lysosomes and induces changes in mitochondrial ATP. This method uses 13 nm AuNPs as loading materials to construct a logic-gated sensor for pH and zinc ion regulation within lysosomes and for TRPML1 mRNA in the cytoplasm. It also uses 5 nm AuNPs as loading materials to construct a sensor targeting mitochondrial ATP for cell imaging. This method enables the detection of mRNA and zinc ions in the cytoplasm, lysosomes, and mitochondria. 2+ ATP-associated ATP sensors, Zn 2+ Three sensors—a sensor, an mRNA sensor, and an X-ray sensor—are used simultaneously to image cells, aiming to answer questions about the mechanisms of ATP changes in mitochondria under the regulation of zinc ion efflux from lysosomes by TRPML1.

The invention discloses mucoprotein hydrogel loaded with cerium-dihydromyricetin nano-enzyme as well as a preparation method and application of the mucoprotein hydrogel, and relates to the technical field of biological medicines. The preparation method comprises the following steps: carrying out coordination reaction on dihydromyricetin and Ce < 4 + > to obtain cerium-dihydromyricetin nano-enzyme; the preparation method comprises the following steps: coupling hyaluronic acid with dopamine to obtain hyaluronic acid-dopamine; the preparation method comprises the following steps: coupling mucoprotein with aminophenylboronic acid to obtain mucoprotein-aminophenylboronic acid; the preparation method comprises the following steps: mixing cerium-dihydromyricetin nano-enzyme, hyaluronic acid-dopamine and mucoprotein-aminophenylboronic acid, and reacting, so as to obtain the mucoprotein hydrogel loaded with the cerium-dihydromyricetin nano-enzyme. The mucoprotein hydrogel loaded with the cerium-dihydromyricetin nano enzyme can be used for effectively treating ulcerative colitis and has an important clinical application value.

The application belongs to the technical field of microorganisms, and discloses a propionic acid-producing propionic acid bacteria NHNK-621 and application of the propionic acid bacteria in preparation of products for improving constipation and memory, the bacteria strain has been preserved in the China Center for Type Culture Collection on November 25, 2024, and the number is CCTCC NO: M 20242631. The propionic acid bacteria NHNK-621 provided by the application has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, up-regulating intestinal defensin and mucin gene expression, in addition, the bacterial biofilm can increase the colonization ability to intestinal epithelial cells, and can be used for preparing products for improving constipation and memory.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ackermania muciniphila and recombinant trichina serine protease carried by a derivative of the ackermania muciniphila to preparation of a medicine for treating intestinal inflammation symptoms. According to the present invention, the ackermann muciniphila and the ackermann muciniphila derivative carrying recombinant trichina serine are firstly disclosed, such that the physical barrier of the intestinal mucosa is repaired through the synergistic effect, the expression of TNF-alpha, IL-6, IL-1beta and other proinflammatory factors is specifically regulated and inhibited, the intestinal flora structure is remodeled, and the intestinal inflammation state is significantly improved; experimental results show that the Ackerman muciniphila and the derivative thereof carrying the recombinant trichina serine protease can significantly relieve weight loss of mice with intestinal inflammation induced by DSS, reduce DAI score, and reverse the phenomena of shortened colon and abnormal swelling of spleen. According to the invention, the probiotics and the parasite-derived protein are combined, so that the method has the advantages of high efficiency, safety and easiness in large-scale production, and a new biological preparation strategy is provided for accurate treatment of IBD.

The invention discloses application of leuconostoc mesenteroides subsp. Mesenteroides in improvement of constipation and depression, and belongs to the technical field of marine microorganisms. The invention discloses a leuconostoc mesenteroides subsp. Mesenteroides NHNK-613, which is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the leuconostoc mesenteroides subsp. Mesenteroides NHNK-613 is CCTCC (China Center for Type Culture Collection) NO: M 20241431. The NHNK-613 has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolizing to generate gamma-aminobutyric acid, inhibiting the growth of candida albicans, inhibiting the formation of candida albicans filaments, combining the candida albicans filaments and up-regulating intestinal defensin and mucoprotein gene expression; the traditional Chinese medicine composition can be used for preparing products for improving constipation and depression.